Form 8-K - Current report

BP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More News

BP plc (NYSE:BP) – BP expects weak margins in its refining business to impact its second-quarter profits...

Form 8-K - Current report

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million...

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for...

Form 4 - Statement of changes in beneficial ownership of securities

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

HilleVax Taps Sean McLoughlin as Chief Operating Officer

By Ben Glickman HilleVax on Thursday named Sean McLoughlin as the vaccine developer's next operating chief. The Boston-based...